The New Gold Dream Drug Company (NGD Ltd) developed a new sleeping pill. The drug is called Unicorn and was approved by the FDA in 2014. In 2015 the company began to notice problems with this drug. People who were prescribed Unicorn reported feeling sleepy during the next day and developing dependence on this drug. The company reacted immediately and stopped selling Unicorn near the end of 2015. In the last six months of 2016, the company was sued by 1,000 people who experienced grogginess and dependency reaction to the sleeping pill. At the end of 2016, the companys attorneys believe there is a 60% chance the company will need to make payments in the range of $1,000 to $5,000 to settle each claim. At the end of 2017, while none of the cases have been resolved, the companys attorneys now believe there is an 80% chance the company will need to make payments in the range of $2,000 to $7,000 to settle each claim. In 2018, 400 claims were settled at a total cost of $1.2 million. Based on this experience, the company believes 30% of the remaining cases will be settled for $3,000 each, 50% will be settled for $5,000 and 20% will be settled for $10,000 each. The company is in the process of first time adoption of IFRS and needs to report under US GAAP and IFRS, as required by IFRS 1. Using US GAAP and IFRS, show what journal entries would be required in 2015, 2016, 2017 and 2018.